172 related articles for article (PubMed ID: 37038822)
21. Searching for Answers: Information-Seeking by Young People At-Risk for Huntington's Disease.
Chase CL; Yashar BM; Swope C; Albin RL; Uhlmann WR
J Huntingtons Dis; 2022; 11(3):337-346. PubMed ID: 35570496
[TBL] [Abstract][Full Text] [Related]
22. Dilemmas when talking about Huntington's disease: A qualitative study of offspring and caregiver experiences in Norway.
Kjoelaas S; Jensen TK; Feragen KB
J Genet Couns; 2022 Dec; 31(6):1349-1362. PubMed ID: 35903951
[TBL] [Abstract][Full Text] [Related]
23. The Huntington's Disease Gene Discovery.
Franklin GL; Teive HAG; Tensini FS; Camargo CHF; de Lima NSC; de Dos Santos DC; Meira AT; Tabrizi SJ
Mov Disord; 2024 Feb; 39(2):227-234. PubMed ID: 38179605
[TBL] [Abstract][Full Text] [Related]
24. Huntington's Disease Clinical Trials Corner: November 2022.
Estevez-Fraga C; Tabrizi SJ; Wild EJ
J Huntingtons Dis; 2022; 11(4):351-367. PubMed ID: 36463457
[TBL] [Abstract][Full Text] [Related]
25. Disease Burden of Huntington's Disease (HD) on People Living with HD and Care Partners in Canada.
Shaw E; Mayer M; Ekwaru P; McMullen S; Graves E; Wu JW; Budd N; Maturi B; Cowling T; Mestre TA
J Huntingtons Dis; 2022; 11(2):179-193. PubMed ID: 35342095
[TBL] [Abstract][Full Text] [Related]
26. Huntington's Disease Clinical Trials Corner: March 2024.
Estevez-Fraga C; Tabrizi SJ; Wild EJ
J Huntingtons Dis; 2024; 13(1):1-14. PubMed ID: 38489195
[TBL] [Abstract][Full Text] [Related]
27. Prospects for neuroprotective therapies in prodromal Huntington's disease.
Chandra A; Johri A; Beal MF
Mov Disord; 2014 Mar; 29(3):285-93. PubMed ID: 24573776
[TBL] [Abstract][Full Text] [Related]
28. Stem Cells for Huntington's Disease (SC4HD): An International Consortium to Facilitate Stem Cell-Based Therapy for Huntington's Disease.
SC4HD Consortium
J Huntingtons Dis; 2021; 10(2):221-226. PubMed ID: 33814456
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory Strategies for Huntington's Disease Treatment.
Colpo GD; Rocha NP; Stimming EF; Teixeira AL
CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
[TBL] [Abstract][Full Text] [Related]
30. Focusing the pivotal role of nanotechnology in Huntington's disease: an insight into the recent advancements.
Singh S; Hema ; Sharma N; Sachdeva M; Behl T; Zahoor I; Fuloria NK; Sekar M; Fuloria S; Subramaniyan V; Alsubayiel AM; Dailah HG; Naved T; Bhatia S; Al-Harrasi A; Aleya L
Environ Sci Pollut Res Int; 2022 Oct; 29(49):73809-73827. PubMed ID: 36100788
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting of Huntington's disease: Molecular and clinical approaches.
Kumar D; Hasan GM; Islam A; Hassan MI
Biochem Biophys Res Commun; 2023 May; 655():18-24. PubMed ID: 36913762
[TBL] [Abstract][Full Text] [Related]
32. Development of a community-based exercise program for people diagnosed and at-risk for Huntington's disease: A clinical report.
Clark D; Danzl MM; Ulanowski E
Physiother Theory Pract; 2016; 32(3):232-9. PubMed ID: 27046737
[TBL] [Abstract][Full Text] [Related]
33. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
[TBL] [Abstract][Full Text] [Related]
34. Huntington's Disease Clinical Trials Corner: August 2023.
Estevez-Fraga C; Tabrizi SJ; Wild EJ
J Huntingtons Dis; 2023; 12(2):169-185. PubMed ID: 37483021
[TBL] [Abstract][Full Text] [Related]
35. Is retina affected in Huntington's disease? Is optical coherence tomography a good biomarker?
Dusek P; Kopal A; Brichova M; Roth J; Ulmanova O; Klempir J; Preiningerova JL
PLoS One; 2023; 18(2):e0282175. PubMed ID: 36827300
[TBL] [Abstract][Full Text] [Related]
36. Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.
Sampaio C; Borowsky B; Reilmann R
Mov Disord; 2014 Sep; 29(11):1419-28. PubMed ID: 25216371
[TBL] [Abstract][Full Text] [Related]
37. Huntington's Disease Clinical Trials Corner: April 2020.
Rodrigues FB; Wild EJ
J Huntingtons Dis; 2020; 9(2):185-197. PubMed ID: 32250312
[TBL] [Abstract][Full Text] [Related]
38. Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform.
Symonds AL; Macerollo A; Foy K; Alusi SH; Davies R
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065918
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic criteria for Huntington's disease based on natural history.
Reilmann R; Leavitt BR; Ross CA
Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
[TBL] [Abstract][Full Text] [Related]
40. Huntington's disease: Neuropsychiatric manifestations of Huntington's disease.
Goh AM; Wibawa P; Loi SM; Walterfang M; Velakoulis D; Looi JC
Australas Psychiatry; 2018 Aug; 26(4):366-375. PubMed ID: 30012004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
